Telefonaktiebolaget LM Ericsson v Lava International Ltd (2016)
High Court of Delhi
Latest update: . Case: Hanmi Pharm Co Ltd v Controller General of Patents and Designs. Doctrine: Amendment Before the Controller.
High Court of Delhi·V. Kameswar Rao J·Single Judge·Decided 2 March 2020
An application to exclude the plaintiffs' in-house expert from the confidentiality club was dismissed: the inspection order had not limited the expert to an external one.
Genentech Inc v Drugs Controller General of India, Ali on Patents, www.aop.onl/genentech
“By this order, I shall decide the instant application filed by the defendant No.3” (para 1), the applicant’s prayer being “that the inspection to be carried out of the applicant’s documents in terms of orders dated April 25, 2016 and February 12, 2020 should be, by an independent expert on behalf of plaintiffs.” (para 2) The applicant contended that “confidentiality clubs are constituted with a view to ensure that the sanctity and confidentiality of business and commercially sensitive information / material filed by a party is maintained”, and objected that the named expert “is an internal / in-house representative of the plaintiff No.2 Company”. (para 4) It relied, among other orders, on Ericsson v Lava (2016), where this Court had allowed inspection only by “not more than three lawyers (who are not and have not been in-house lawyers of one of the parties) and not more than two external expert witnesses, who alone will be entitled to see the aforesaid confidential documents/patent license agreements”. (para 8)
The Court framed “the only issue, which arises for consideration is whether the Confidentiality Club to be formed shall only include an external expert and not an internal expert, as suggested by the applicant” (para 11), and held that the earlier order “has not limited the expert to be an external expert. If the Court meant that way, it would have said so.” (para 11) Finding the applicant’s cited orders “distinguishable in the facts of this case, more particularly, in view of the history of litigation between the parties” (para 13), “The application filed by the applicant is dismissed.” (para 13)
Section 103 of the Patents Act. Under sub-section 3 of Section 103, “the disclosure may be made confidentially to the advocate of the other party or to an independent expert mutually agreed upon”, for “A trade secrets may make or break a company hence need to be protected. Once such disclosure is made or is misused by a competitor no order of the Court can save the company from loss or could retrieve it to its original position.” (para 8)
A confidentiality club with restricted access. “such confidential club though can be created but the access to information may be restricted, especially in patent cases. Hence there is no impediment if the confidential club is created and its access is limited”. (para 9)
Internal or external expert. The earlier order “has not limited the expert to be an external expert. If the Court meant that way, it would have said so”, the liberty to amend the pleadings being “only possible, if the plaintiffs are represented by an internal expert”; and in any event “even if inspection is carried out by an external expert, still he has to divulge the information acquired from the documents to enable the plaintiff carry out the amendments to establish its claim in the suit.” (para 11)
Rule 17 and commercial suits. “the reliance placed by Mr. Lall on Rule 17 is misplaced as it primarily applicable to a commercial suit, which is not the case here”, though “the principles akin to Rule 17 have been made applicable to the case in hand”. (para 12)
Procedure. Disposition. The applicant’s cited orders being “distinguishable in the facts of this case, more particularly, in view of the history of litigation between the parties”, “The application filed by the applicant is dismissed.” (para 13)
No later judicial treatment and no further appeal traced as of 2 November 2026.
Case page · Page updated 13 November 2026
www.aop.onl/genentech